One size doesn’t fit all? FDA may soften some cell therapy regs
The Pink Sheet just broke the story that the FDA may change up its oversight of the cell therapy space. This possible shift could drop the oversight bar somewhat for certain products. Most likely it’d be those with lower anticipated risks. The Pink Sheet piece by Sue Sutter is titled US FDA To Explore New Regulatory Pathways […]
One size doesn’t fit all? FDA may soften some cell therapy regs Read More »